Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Context Therapeutics Inc. has granted non-qualified stock option awards to a new employee as an inducement for accepting employment, totaling 30,000 shares of common stock [1][2] - The stock options were granted outside of the company's 2021 Long-Term Performance Incentive Plan, with an exercise price of $0.97 per share, equal to the closing price on the grant date [2] - The stock options have a 10-year term and will vest over four years, with one-fourth vesting on the first anniversary and the remainder vesting in thirty-six equal monthly installments [3] Company Overview - Context Therapeutics Inc. is a biopharmaceutical company focused on advancing T cell engaging bispecific antibodies for solid tumors [4] - The company is developing a portfolio of TCE bispecific therapeutics, including CTIM-76, CT-95, and CT-202 [4] - Context Therapeutics is headquartered in Philadelphia and provides additional information on its website and social media platforms [4]